Respiratory syncytial virus vaccine(Moderna Therapeutics)

N/A

Report date: 2026/05/13 15:37:22

Base Information

Drug NameRespiratory syncytial virus vaccine(Moderna Therapeutics)
Drug Alias Namenucleoside modified mRNA encoding the RSV F glycoproteinmRESVIAmRNA-1345
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metapneumovirus infectionsRespiratory Syncytial Virus Infections +[5] 
Global Approved IndicationsRespiratory Syncytial Virus Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/05/31
Country/TerritoryBelgiumCanadaPanama +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesModerna Inc
China Registration ClassN/A

Develop Information

Active CompaniesModerna IncModerna Biotech Spain SL
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Metapneumovirus infectionsRespiratory Syncytial Virus Infections +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A